Investment
Features
FeesSafety
Academy
More
Pluang+

Texas Roadhouse posts strong sales growth and market share gains despite beef inflation.

Analyst Insights
17 Sep 2026
Seeking Alpha
View Source
Bullish
Texas Roadhouse posts strong sales growth and market share gains despite beef inflation.

Texas Roadhouse reported a 6.2% same-store sales increase, driven by a 3% rise in customer traffic and average unit volumes near $9.5 million, exceeding expectations. The company benefits from disciplined pricing below inflation and improved gross margins due to favorable sirloin prices. However, management expects cost of goods sold inflation of 2-3% in Q3 and around 5% in Q4, cautioning that recent margin gains should not be annualized. The outlook remains positive with a 'Buy' rating and a $190 price target, supported by strong unit economics and growth potential as beef prices stabilize.

Texas Roadhouse stock and its recent performance provide context for consumer cyclical sector trends. For readers following this sector, here is Pluang's market snapshot as of Sep 17, 2026 18:51 WIB: of 105 priced Consumer Cyclical-sector US stocks tradable on Pluang, 89 rose and 12 fell today. Notable movers include Carvana Co (CVNA) at USD 66.61 with a 1-day change of +1.85%, Quantumscape Corp (QS) at USD 5.09 with +1.80%, and Macy's Inc (M) at USD 22.20 with +1.79%.

More News

Sigenergy debuts AI-powered energy solutions and new partnerships at Malaysia's IGEM 2026.

Sigenergy debuts AI-powered energy solutions and new partnerships at Malaysia's IGEM 2026.

At Malaysia's IGEM 2026, Sigenergy showcased its latest AI-driven energy technologies, including smart storage and inverter systems, highlighting its role in advancing sustainable energy. The company also signed MOUs with local partners Milieu and YT...

Market News
Bullish
3 hours ago
Entrada Therapeutics rated Buy with $8.50 target, expects higher drug dosing results in 2027.

Entrada Therapeutics rated Buy with $8.50 target, expects higher drug dosing results in 2027.

Entrada Therapeutics is rated Buy with a fair value of $8.50, implying about 52% upside from the current $5.61 price. The company’s Duchenne muscular dystrophy drug ENTR-601-44 showed a disappointing initial increase in dystrophin, but this is attrib...

Analyst Insights
Neutral
4 hours ago
Ten-year Treasury yields hit 5.36% amid systemic debt concerns and strong stock market gains.

Ten-year Treasury yields hit 5.36% amid systemic debt concerns and strong stock market gains.

Ten-year U.S. Treasury yields reached 5.36% intraday, reflecting growing systemic sovereign debt issues. Despite these concerns, the stock market showed strength with the S&P 500 rising 1.2% and the Dow gaining 0.9%, supported by a 43-week expansion ...

Market News
Neutral
4 hours ago
Pump.fun's token buyback drops as daily revenue falls 16%, impacting price support until April 2027.

Pump.fun's token buyback drops as daily revenue falls 16%, impacting price support until April 2027.

Pump.fun's daily revenue, which funds half of its token buyback and burn program, fell 16% from $1.89 million on October 5 to $1.59 million on October 9, causing the token price to drop 16.8% from its weekly high. The buyback program, running until A...

Protocol Fundamentals
Bearish
4 hours ago
Alphamin Resources offers a promising buy with stable tin mines and growth potential in DRC.

Alphamin Resources offers a promising buy with stable tin mines and growth potential in DRC.

Alphamin Resources Corp. operates two profitable tin mines in the Democratic Republic of Congo and is focusing on exploration around its Bisie resource, offering speculative growth potential. The company's current operations are stable and profitable...

Analyst Insights
Bullish
4 hours ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App